Compare PCRX & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | FTH |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 835.7M |
| IPO Year | 2010 | 2021 |
| Metric | PCRX | FTH |
|---|---|---|
| Price | $36.35 | $19.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 16 |
| Target Price | $33.57 | ★ $56.14 |
| AVG Volume (30 Days) | ★ 2.1M | 331.0K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $3.84 | N/A |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | $191.29 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $17.50 |
| 52 Week High | $36.67 | $42.14 |
| Indicator | PCRX | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 83.97 | 29.10 |
| Support Level | $21.78 | N/A |
| Resistance Level | N/A | $36.63 |
| Average True Range (ATR) | 0.40 | 2.32 |
| MACD | 0.89 | -0.72 |
| Stochastic Oscillator | 97.44 | 11.64 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.